IPU welcomes PSI Guidelines on Codeine Medicines
Monday, 21 December 2009 12:52
The Irish Pharmacy Union (IPU), which represents 1,800 pharmacists, today welcomed the announcement by the Pharmaceutical Society of Ireland (PSI) that it had published draft guidance for pharmacists on the safe supply of non-prescription medicinal products containing codeine. The announcement comes a few weeks after the IPU and the Irish Pharmaceutical Healthcare Association (IPHA) jointly produced a protocol to assist pharmacists in the sale of codeine-containing medicines.
The IPU and IPHA ran a public awareness initiative in August 2007 highlighting the safe use of pain relievers and the problems associated with their overuse or abuse. In particular, people were advised to speak to their pharmacist on the appropriate use of codeine, which is contained in a wide range of pain relievers and available from pharmacies without a prescription. The campaign recommended that people always follow the instructions which accompany the medicines and not use them for longer than stated on the pack, unless advised to do so by their doctor.
“Non-prescription pain relievers can be very effective in relieving the symptoms of headaches and other forms of pain when taken correctly,” said Keith O’Hourihane of Pharmacy First Plus, Cork and Chairman of the IPU’s Community Pharmacy Committee. “However, taking medicines which contain codeine for longer than instructed or misusing them can lead to physical and psychological dependence and result in withdrawal symptoms, such as restlessness and irritability once the patient stops taking the medication.”
Patients who use pain relievers which contain codeine for longer than three days at a time or exceed the recommended dosage could also experience what is called rebound headaches. Pain relievers offer quick relief for occasional headaches but incorrect use may actually contribute to headaches rather than easing them.
Pamela Logan, Director of Pharmacy Services in the IPU, advised: “People who misuse non prescription pain relievers can become addicted to certain substances and suffer withdrawal symptoms if they do not continue to take them. The pattern of usage then becomes a vicious circle resulting in dependency. We hope that by highlighting this issue, patients will be mindful of the problems that can result from the misuse of such medications and will consult with their pharmacist who can advise them on appropriate medical care, which will minimise any potential risks to themselves or their families.”
